EGFR and prostate carcinoma: To quantitate cell motility, an in vitro wound healing assay was performed and demonstrated that the addition of STAT3 antisense oligonucleotides and the EGFR signalling pathway inhibitor PD153035 (Figure 2A) or siRNA-mediated downregulation (Figure 2B) greatly decreased the migration distance of NR6WT fibroblast cell and DU145WT and PC3 human prostate cancer cells.